The bear case worth considering ...AI assisted
While it sounds counterintuitive that DaVita and Fresenius would restrict a drug that Medicare covers at 100% of its Average Sales Price (ASP), the answer lies in the harsh financial realities of the post-2026 Medicare bundling mechanics.To Large Dialysis Organizations (LDOs), "100% covered" does not mean profitable.
In fact, under the 2027 CMS rulemaking environment, it acts as a cap on revenue that completely strips away their corporate profit engines.1. 100% of ASP Equals Zero Profit MarginUnder TDAPA, Medicare pays the facility exactly 100% of the drug's Average Sales Price (ASP).
The Math: If Oxylanthanum Carbonate (OLC) costs $500 a month to procure, Medicare pays DaVita exactly $500.
The Problem: There is 0% profit margin built into this transaction for the LDO.
For a massive corporation driven by shareholder margins, a drug that yields zero spread is a financial dead weight.
2. The Legacy Generics Will Be "The Cash Cows"
The critical shift occurs on January 1, 2027, when the initial class-level TDAPA period expires for the six legacy phosphate binders (like generic sevelamer and calcium acetate).
The Base Bundle Boost:
In 2027, CMS will permanently roll the historical cost of those legacy binders into the core, flat-rate dialysis base bundle.
The Arbitrage Opportunity:
Once those drugs are inside the flat base rate, CMS pays DaVita and Fresenius a fixed lump sum per treatment, regardless of how cheaply they buy the binders.
The Incentive:
The LDOs will use their massive buying power (controlling ~75% of the US market) to purchase dirt-cheap generic sevelamer or calcium acetate for pennies, while pocketing the entire fixed Medicare bundle payment.
Utilizing OLC instead completely bypasses this highly lucrative "spread."
3. Unreimbursed Operational OverheadDispensing an oral medication is vastly different from administering an IV drug clinic-side.
To distribute oral OLC, DaVita and Fresenius must shoulder massive infrastructure costs:Operating complex specialty pharmacy hubs.
Paying for shipping, inventory tracking, and climate-controlled storage.Diverting nursing labor to track adherence and manage pill distribution.
Because TDAPA only reimburses the exact ingredient cost of the drug (100% ASP), the LDOs are forced to absorb 100% of these logistical expenses out-of-pocket. Using a generic drug inside the base bundle allows them to utilize their margins to pay for operations; using OLC represents a net operational loss.
4. The 20% Coinsurance Collection NightmareWhile Medicare covers its portion, "100% of ASP" actually follows standard Medicare Part B rules: Medicare pays 80%, and the patient or their secondary insurance is responsible for a 20% coinsurance copay.Because OLC is a premium, nanoparticle-formulated brand drug, its ASP will be high. A 20% copay on an expensive drug is a major burden for a dialysis patient.Dialysis clinics historically struggle to collect this 20% from low-income patients, and federal anti-kickback laws explicitly prohibit manufacturers from giving free copay cards to Medicare patients.
If a patient cannot pay, DaVita and Fresenius must write it off as bad debt, turning a "100% covered" drug into a financial loss.How the LDO "Niche" Restriction WorksTo protect their margins, DaVita and Fresenius will implement strict Formulary Step-Therapy Protocols.
A physician will not be allowed to open a chart and freely select OLC.
Instead, the LDO's software will mandate that a patient must "fail" on cheap, bundled generic calcium acetate, and then "fail" on generic sevelamer, before the system authorizes the clinic pharmacy to order the premium TDAPA-bound OLC.
Kiwi
Market Data 
Markets 
